GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 1,657 Shares of Stock

by · The Markets Daily

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CEO Katherine Stueland sold 1,657 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.36. Following the transaction, the chief executive officer now owns 3,937 shares of the company’s stock, valued at approximately $308,975.76. This represents a 29.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Katherine Stueland also recently made the following trade(s):

  • On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
  • On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08.
  • On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total transaction of $805,951.75.
  • On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $279,590.57.
  • On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total transaction of $1,569,074.38.
  • On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total value of $1,628,651.84.

GeneDx Stock Down 3.9 %

WGS stock opened at $74.85 on Friday. The company’s 50 day moving average is $78.29 and its two-hundred day moving average is $57.97. GeneDx Holdings Corp. has a twelve month low of $3.62 and a twelve month high of $98.87. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock has a market cap of $2.06 billion, a P/E ratio of -24.07 and a beta of 2.02.

GeneDx (NASDAQ:WGS – Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. During the same period in the previous year, the company earned ($0.82) earnings per share. GeneDx’s quarterly revenue was up 44.3% compared to the same quarter last year. Research analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Institutional Trading of GeneDx

A number of large investors have recently made changes to their positions in the company. MCF Advisors LLC increased its position in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after buying an additional 182 shares during the period. Global Retirement Partners LLC acquired a new position in shares of GeneDx in the 4th quarter valued at $28,000. CWM LLC purchased a new stake in GeneDx in the 3rd quarter valued at $89,000. SG Americas Securities LLC acquired a new stake in GeneDx during the 3rd quarter worth $198,000. Finally, Evolution Wealth Advisors LLC acquired a new position in GeneDx in the fourth quarter valued at $202,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on WGS shares. Wells Fargo & Company increased their price target on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Craig Hallum raised their target price on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. The Goldman Sachs Group boosted their price target on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Finally, TD Cowen lifted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $70.67.

Read Our Latest Research Report on GeneDx

About GeneDx

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Featured Articles